| scholarly article | Q13442814 |
| P2093 | author name string | David S H Bell | |
| P2860 | cites work | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 |
| Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium | Q28304462 | ||
| Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study | Q34257350 | ||
| Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes | Q43901642 | ||
| Impairment of myocardial protection in type 2 diabetic patients | Q44306774 | ||
| Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics | Q44588093 | ||
| Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk | Q45069543 | ||
| Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. | Q50535464 | ||
| Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. | Q51555079 | ||
| Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction | Q71574857 | ||
| Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans | Q71698249 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 185-186 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Canadian Medical Association Journal | Q5030320 |
| P1476 | title | Do sulfonylurea drugs increase the risk of cardiac events? | |
| P478 | volume | 174 |
| Q45074541 | Cardiovascular mortality and oral antidiabetic drugs: protocol for a systematic review and network meta-analysis. |
| Q38364806 | Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. |
| Q38046641 | Combine and conquer: advantages and disadvantages of fixed-dose combination therapy |
| Q58394636 | Comment on: Evans JM, Ogston SA, Emslie-Smith A, Morris A (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936 |
| Q37101613 | Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care |
| Q49716961 | Effect of glucose-lowering therapies on heart failure |
| Q40148424 | Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions |
| Q27024469 | Glycemic control and cardiovascular disease: what's a doctor to do? |
| Q36108287 | Inpatient treatment of type 2 diabetes |
| Q38281461 | Mortality risk among sulfonylureas: a systematic review and network meta-analysis |
| Q46081465 | Pantalone et al.: the risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis |
| Q30234356 | Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence |
| Q38330456 | Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. |
| Q36603962 | Protective effects of Quercus salicina on alloxan-induced oxidative stress in HIT-T15 pancreatic β cells |
| Q38845574 | Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs |
| Q37460057 | Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. |
| Q34541875 | Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. |
| Q37878493 | Sulfonylureas: do we need to introspect safety again? |
| Q46132812 | The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis |
| Q38137389 | What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus? |
| Q87157899 | [Pharmaceutical and insulin therapy of diabetes mellitus type 2. Update] |
Search more.